The concept of chronic disease in the palliative treatment of oncologic patients: Current swiss data and insights in the context of breast and ovarian cancer;Das konzept der chronischen erkrankung in der palliativbehandlung onkologischer patientinnen: Schweizer daten und fakten zu mamma- und ovarialkarzinom

Praxis

Volumn 99, Issue 23, 2010, Pages 1413-1421

  Güth, Uwe ^a   Kilic, N ^b   Schmid, S ^a  

^a UNIVERSITY WOMEN S HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Breast cancer; Chronic disease; Oncology; Ovarian cancer; Palliative medicine

Indexed keywords

BREAST CANCER; CANCER PATIENT; CHRONIC DISEASE; HUMAN; OVARY CANCER; PALLIATIVE THERAPY; QUALITY OF LIFE; RETROSPECTIVE STUDY; SHORT SURVEY;

EID: 78649367532     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/1661-8157/a000309     Document Type: Short Survey

References (40)

1. Lubkin I, Larsen P. Chronic Illness, fifth edition. Sudbury, MA: Jones & Bartlett, 2002.
2. Norris S, Glasgow R, Engelgau M, O'Connor P, McCulloch D. Chronic disease management: a definition and systematic approach to component interventions. Disease Management & Health Outcomes 2003;11:477-488. (Pubitemid 37056112)
3. Bukowski RM, Ozols RF, Markman M. The management of recurrent ovarian cancer. Semin Oncol 2007;34(2 Suppl 2):S1-15.
4. Markman M. Unresolved issues in the chemotherapeutic management of gynecologic malignancies. Semin Oncol 2006;33(2 Suppl 6):S33-38.
5. Michener CM, Belinson JL. Modern management of recurrent ovarian carcinoma. A systematic approach to a chronic disease. Oncology (Williston Park) 2005;19:1277-1285; discussion 1285, 1288,1293.
6. Fennell P. The chronic illness workbook: strategies and solutions for taking back your life. second edition. Delmar, N.Y. Spring harbor press, 2006.
7. Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007;14:195-208.
8. Herzog TJ. The current treatment of recurrent ovarian cancer. Curr Oncol Rep 2006;8:448-454. (Pubitemid 44697774)
9. Modesitt SC, Jazaeri AA. Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Expert Opin Pharmacother 2007;8:2293-2305. (Pubitemid 350001591)
10. Ozols R, Rubin S, Thomas G, Robboy S. Epithelial Ovarian Cancer. In: Hoskins W, Perez C, Young R, et al.(eds.) Principles and Practice of Gynecologic Oncology, fourth edition. Philadelphia: Lippincott Williams & Wilkins, 2005;895-987.
11. Ozols RF. Challenges for chemotherapy in ovarian cancer. Ann Oncol 2006;17 (Suppl 5):v181-187. (Pubitemid 43994856)
12. Guth U, Kann SR, Huang DJ, Schotzau A, Holzgreve W, Wight E. Systemic therapy developments and their effects regarding the current concept of recurrent ovarian carcinoma as a chronic disease. Arch Gynecol Obstet 2009;280:719-724.
13. Markman M. Why study third-, fourth-, fifth-, ...line chemotherapy of ovarian cancer? Gynecol Oncol 2001;83:449-450. (Pubitemid 33139701)
14. Gueth U, Huang DJ, Schoetzau A, Holzgreve W, Wight E. Systemic therapy of metastatic breast cancer: the truth beyond the clinical trials. Oncology 2009;76:247-253.
15. Ellis M, Hayes D, Lippman M. Treatment of metastatic breast cancer. In: Harris J, Lippman M, Morrow M, et al. (eds.) Diseases of the Breast, third edition. Philadelphia: Lippincott Williams & Wilkins, 2004;1101-1159.
16. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-205. (Pubitemid 26264869)
17. Guth U, Huang DJ, Dirnhofer S, Rochlitz C, Wight E. Distant metastatic breast cancer as an incurable disease: a tenet with a need for revision. Cancer J 2009;15:81-86.
18. Hortobagyi GN: Can we cure limited metastatic breast cancer? J Clin Oncol 2002;20:620-623.
19. Nieto Y, Nawaz S, Jones RB, et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 2002;20:707-718. (Pubitemid 34111378)
20. Rivera E, Holmes FA, Buzdar AU, et al. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J 2002;8:2-9. (Pubitemid 34118477)
21. Sledge GW, Jr.: Should we dream the impossible dream? The meaning of long-term survival in metastatic breast cancer. J Clin Oncol 1996;14:2191-2193.
22. Chung CT, Carlson RW. Goals and objectives in the management of metastatic breast cancer. Oncologist 2003;8:514-520. (Pubitemid 37467366)
23. du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005;16 (Suppl 8):viii7-viii12.
24. Gralow JR. Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat 2005;89 (Suppl 1):S9-S15. (Pubitemid 40487009)
25. Nicolini A, Giardino R, Carpi A, et al. Metastatic breast cancer: an updating. Biomed Pharmacother 2006;60:548-556.
26. Andre F, Slimane K, Bachelot T, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 2004;22:3302-3308. (Pubitemid 41103686)
27. Chia SK, Speers CH, D'Yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007;110:973-979. (Pubitemid 47312861)
28. Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998;16:3439-3460. (Pubitemid 28481644)
29. Stockler M, Wilcken NR, Ghersi D, Simes RJ Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 2000;26:151-168. (Pubitemid 30330662)
30. Cardoso F, Di LA, Lohrisch C, Bernard C, Ferreira F, Piccart MJ Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 2002;13:197-207. (Pubitemid 34704970)
31. Wildiers H, Kunkler I, Biganzoli L, et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 2007;8:1101-1115. (Pubitemid 350182967)
32. Guth U, Huang DJ, Schotzau A, Wight E. Is the current concept of recurrent ovarian carcinoma as a chronic disease also applicable in platinum resistant patients? Arch Gynecol Obstet 2010;281:339-344.
33. Chan JK, Cheung MK, Husain A, et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 2006;108:521-528. (Pubitemid 44337091)
34. Friedlander M, Butow P, Stockler M, et al.: Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. Int J Gynecol Cancer 2009;19 (Suppl 2):S44-48.
35. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-2106.
36. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24:4699-4707. (Pubitemid 46630933)
37. Ferrero JM, Weber B, Geay JF, et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 2007;18:263-268. (Pubitemid 46323091)
38. Pfisterer J, Ledermann JA. Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol 2006;33 (2 Suppl 6):S12-16.
39. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]. Ann Oncol 1997;8:963-968. (Pubitemid 27475726)
40. Rocconi RP, Case AS, Straughn JM, Jr., Estes JM, Partridge EE. Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis. Cancer 2006;107:536-543. (Pubitemid 44107214)